Abstract P4-12-29: Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer
Year: 2013
Type: conference-abstract
Source: Cancer Research
Institutions: Indiana University Health, University of California, San Francisco, The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Merrimack Pharmaceuticals (United States), UCSF Helen Diller Family Comprehensive Cancer Center, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1964262389